November 14, 2017 06:56 AM ESTUpdated 10:24 AM

Parker Institute, MD Anderson and Seres developing a microbiome/PD-1/L1 combo; CRISPR-Cas antimicrobial biotech Locus raises $17M

John Carroll

Editor & Founder

→ Just days ago, MD Anderson researcher Jennifer Wargo and colleagues published new research that showed how the gut microbiome played a big role in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Parker Institute, MD Anderson and Seres developing a microbiome/PD-1/L1 combo; CRISPR-Cas antimicrobial biotech Locus raises $17M

John Carroll

Editor & Founder

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Biohaven stock sinks on three-month delay for neuro drug's FDA approval decision

Merck KGaA will continue to add a tariff surcharge for US customers

Hengrui, one of China's leading biotechs, anticipates $1.2B in proposed Hong Kong listing

FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer

Sanofi touts $20B investment in US over five years

RFK Jr. defends HHS staff cuts, reorganization plans in House, Senate hearings

Park­er In­sti­tute, MD An­der­son and Seres de­vel­op­ing a mi­cro­bio­me/PD-1/L1 com­bo; CRISPR-Cas an­timi­cro­bial biotech Lo­cus rais­es $17M

Editor & Founder

Sign up to read this article for free.

more like this

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Parker Institute, MD Anderson and Seres developing a microbiome/PD-1/L1 combo; CRISPR-Cas antimicrobial biotech Locus raises $17M